Esperion Provides Update on Common Stock Trading Activity
May 22 2017 - 8:05AM
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management
Company focused on developing and commercializing convenient,
complementary, cost-effective, once-daily, oral therapies for the
treatment of patients with elevated low density lipoprotein
cholesterol (LDL-C), today provided an update to its shareholders
regarding recent trading activity in the company's common stock.
On Thursday, May 18, 2017 a report on Esperion
and bempedoic acid containing inaccurate information was issued.
Esperion believes the report was intended to discredit the
company and its oral LDL-C lowering therapies in Phase 3 clinical
development. Esperion generally does not respond to blog posts,
sales commentary, investor reports or analyst communications.
However, in this case, Esperion is providing an update and issued a
blog post given the report's various misinterpretations and
misstatements of facts regarding bempedoic acid and its efficacy
results, safety and tolerability profile and the design of the
cardiovascular outcomes trial.
Esperion wishes to assure its shareholders,
collaboration partners, and colleagues that Esperion remains
dedicated to advancing the clinical development of bempedoic acid
for patients with hypercholesterolemia who require additional LDL-C
lowering and for their treating physicians, and to generating
significant long-term value for its shareholders.
Bempedoic Acid
With a targeted mechanism of action, bempedoic
acid is a first-in-class, orally available, once-daily ACL
inhibitor that reduces cholesterol biosynthesis and lowers elevated
levels of LDL-C by up-regulating the LDL receptor, and may
potentially be associated with a lower occurrence of muscle-related
side effects. Completed Phase 1 and 2 studies in more than 800
patients treated with bempedoic acid have produced clinically
relevant LDL-C lowering results of up to 30 percent as monotherapy,
approximately 50 percent in combination with ezetimibe, and an
incremental 20+ percent when added to stable statin therapy.
Esperion's Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more
than 20 percent of the population, have elevated LDL-C; an
additional 73 million people in Europe and 30 million people in
Japan also live with elevated LDL-C. Esperion's mission as the
Lipid Management Company is to provide patients and physicians with
convenient, complementary, cost-effective, once-daily, oral
therapies to significantly reduce elevated levels of LDL-C in
patients inadequately treated with current lipid-modifying
therapies. It is estimated that 40 million patients in the
U.S. are taking statins with approximately 5-20 percent of
these patients only able to tolerate less than the lowest approved
daily starting dose of their statin and considered statin
intolerant. Esperion-discovered and developed, bempedoic acid is a
targeted LDL-C lowering therapy in Phase 3 development. The Company
has two Phase 3 products in development: 1) bempedoic acid
(monotherapy) an oral, once-daily pill, and 2) an, oral, once-daily
fixed dose combination pill of bempedoic acid and ezetimibe
(BA+EZ).
The Lipid Management Company
Esperion Therapeutics, Inc. is the Lipid
Management Company passionately committed to developing and
commercializing convenient, complementary, cost-effective,
once-daily, oral therapies for the treatment of patients with
elevated LDL-C. Through scientific and clinical excellence, and a
deep understanding of cholesterol biology, the experienced lipid
management team at Esperion is committed to developing new LDL-C
lowering therapies that will make a substantial impact on reducing
global CVD; the leading cause of death around the world. Bempedoic
acid, the Company's lead product candidate, is a targeted therapy
that has been shown to significantly reduce elevated LDL-C levels
in patients with hypercholesterolemia, including patients
inadequately treated with current lipid-modifying therapies. For
more information, please visit www.esperion.com and
follow us on Twitter at https://twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws, including statements regarding the
regulatory approval pathway for bempedoic acid and the therapeutic
potential of, and clinical development plan for, bempedoic acid.
Any express or implied statements contained in this press release
that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause Esperion's actual results
to differ significantly from those projected, including, without
limitation, the risks detailed in Esperion's filings with the
Securities and Exchange Commission. Esperion disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, other than to the
extent required by law.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2024 to May 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2023 to May 2024